These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1464 related articles for article (PubMed ID: 15842577)

  • 1. Valdecoxib is associated with improved dyspepsia-related health compared with nonspecific NSAIDs in patients with osteoarthritis or rheumatoid arthritis.
    Rabeneck L; Goldstein JL; Vu A; Mayne TJ; Rublee DA
    Am J Gastroenterol; 2005 May; 100(5):1043-50. PubMed ID: 15842577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial.
    Pavelka K; Recker DP; Verburg KM
    Rheumatology (Oxford); 2003 Oct; 42(10):1207-15. PubMed ID: 12810937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-analysis: upper gastrointestinal tolerability of valdecoxib, a cyclooxygenase-2-specific inhibitor, compared with nonspecific nonsteroidal anti-inflammatory drugs among patients with osteoarthritis and rheumatoid arthritis.
    Eisen GM; Goldstein JL; Hanna DB; Rublee DA
    Aliment Pharmacol Ther; 2005 Mar; 21(5):591-8. PubMed ID: 15740543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of valdecoxib in treating the signs and symptoms of severe rheumatoid arthritis: a 12-week, multicenter, randomized, double-blind, placebo-controlled study.
    Gibofsky A; Rodrigues J; Fiechtner J; Berger M; Pan S
    Clin Ther; 2007 Jun; 29(6):1071-85. PubMed ID: 17692722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis.
    Kivitz A; Eisen G; Zhao WW; Bevirt T; Recker DP
    J Fam Pract; 2002 Jun; 51(6):530-7. PubMed ID: 12100776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.
    Bensen WG; Zhao SZ; Burke TA; Zabinski RA; Makuch RW; Maurath CJ; Agrawal NM; Geis GS
    J Rheumatol; 2000 Aug; 27(8):1876-83. PubMed ID: 10955327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of valdecoxib and naproxen in the treatment of rheumatoid arthritis symptoms.
    Williams GW; Kivitz AJ; Brown MT; Verburg KM
    Clin Ther; 2006 Feb; 28(2):204-21. PubMed ID: 16678642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study.
    Singh G; Fort JG; Goldstein JL; Levy RA; Hanrahan PS; Bello AE; Andrade-Ortega L; Wallemark C; Agrawal NM; Eisen GM; Stenson WF; Triadafilopoulos G;
    Am J Med; 2006 Mar; 119(3):255-66. PubMed ID: 16490472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reliability, validity, and responsiveness of severity of dyspepsia assessment (SODA) in a randomized clinical trial of a COX-2-specific inhibitor and traditional NSAID therapy.
    Rabeneck L; Wristers K; Goldstein JL; Eisen G; Dedhiya SD; Burke TA
    Am J Gastroenterol; 2002 Jan; 97(1):32-9. PubMed ID: 11808967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen.
    Makarowski W; Zhao WW; Bevirt T; Recker DP
    Osteoarthritis Cartilage; 2002 Apr; 10(4):290-6. PubMed ID: 11950252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of aceclofenac in the treatment of osteoarthritis: a randomized double-blind comparative clinical trial versus diclofenac - an Indian experience.
    Pareek A; Chandanwale AS; Oak J; Jain UK; Kapoor S
    Curr Med Res Opin; 2006 May; 22(5):977-88. PubMed ID: 16709320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
    Hochberg MC
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and Ibuprofen in the treatment of osteoarthritis of the knee.
    Schiff M; Minic M
    J Rheumatol; 2004 Jul; 31(7):1373-83. PubMed ID: 15229960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measuring dyspepsia-related health in randomized trials: the Severity of Dyspepsia Assessment (SODA) and its use in treatment with NSAIDs and COX-2-specific inhibitors.
    Rabeneck L
    Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii32-9. PubMed ID: 14585916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Celecoxib in osteoarthritis and rheumatoid arthritis: new preparation. As disappointing as rofecoxib.
    Prescrire Int; 2001 Apr; 10(52):46-9. PubMed ID: 11718158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rofecoxib in rheumatoid arthritis: new indication. No better that other NSAIDS.
    Prescrire Int; 2003 Jun; 12(65):89-90. PubMed ID: 12825570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastrointestinal tolerability of NSAIDs in elderly patients: a pooled analysis of 21 randomized clinical trials with celecoxib and nonselective NSAIDs.
    Mallen SR; Essex MN; Zhang R
    Curr Med Res Opin; 2011 Jul; 27(7):1359-66. PubMed ID: 21561397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
    Maetzel A; Krahn M; Naglie G
    Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib.
    Goldstein JL; Eisen GM; Agrawal N; Stenson WF; Kent JD; Verburg KM
    Aliment Pharmacol Ther; 2004 Sep; 20(5):527-38. PubMed ID: 15339324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
    Sowers JR; White WB; Pitt B; Whelton A; Simon LS; Winer N; Kivitz A; van Ingen H; Brabant T; Fort JG;
    Arch Intern Med; 2005 Jan; 165(2):161-8. PubMed ID: 15668361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 74.